BRPI0919882A8 - Métodos para avaliar padrões de rna - Google Patents

Métodos para avaliar padrões de rna

Info

Publication number
BRPI0919882A8
BRPI0919882A8 BRPI0919882A BRPI0919882A BRPI0919882A8 BR PI0919882 A8 BRPI0919882 A8 BR PI0919882A8 BR PI0919882 A BRPI0919882 A BR PI0919882A BR PI0919882 A BRPI0919882 A BR PI0919882A BR PI0919882 A8 BRPI0919882 A8 BR PI0919882A8
Authority
BR
Brazil
Prior art keywords
methods
cancer
rna patterns
evaluate rna
evaluate
Prior art date
Application number
BRPI0919882A
Other languages
English (en)
Inventor
Klass Michael
Kuslich Christine
Poste George
Original Assignee
Caris Life Sciences Luxembourg Holdings
Caris Life Sciences Switzerland Holdings Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Caris Life Sciences Luxembourg Holdings, Caris Life Sciences Switzerland Holdings Gmbh filed Critical Caris Life Sciences Luxembourg Holdings
Publication of BRPI0919882A2 publication Critical patent/BRPI0919882A2/pt
Publication of BRPI0919882A8 publication Critical patent/BRPI0919882A8/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)

Abstract

MÉTODO PARA DISTINGUIR UM CÂNCER DE PRÓSTATA, SISTEMA DE DETECÇÃO,E KIT. A presente invenção refere-se a métodos e composições para a caracterização de tipos de câncer pela avaliação de níveis de RNA, como a determinação de padrão de RNA. O diagnóstico, prognóstico, acompanhamento e tratamento ou um câncer podem ser determinados pela detecção de um ou mais RNAs, como microRNAs.
BRPI0919882A 2008-10-30 2009-10-30 Métodos para avaliar padrões de rna BRPI0919882A8 (pt)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US10974208P 2008-10-30 2008-10-30
US11257108P 2008-11-07 2008-11-07
US11405808P 2008-11-12 2008-11-12
US11404508P 2008-11-12 2008-11-12
US11406508P 2008-11-13 2008-11-13
US15118309P 2009-02-09 2009-02-09
US27804909P 2009-10-02 2009-10-02
US25045409P 2009-10-09 2009-10-09
US25302709P 2009-10-19 2009-10-19
PCT/US2009/062880 WO2010062706A2 (en) 2008-10-30 2009-10-30 Methods for assessing rna patterns

Publications (2)

Publication Number Publication Date
BRPI0919882A2 BRPI0919882A2 (pt) 2016-02-16
BRPI0919882A8 true BRPI0919882A8 (pt) 2017-09-19

Family

ID=42226337

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0919882A BRPI0919882A8 (pt) 2008-10-30 2009-10-30 Métodos para avaliar padrões de rna

Country Status (8)

Country Link
US (3) US7888035B2 (pt)
EP (1) EP2358912B1 (pt)
JP (1) JP2012507300A (pt)
CN (1) CN102308004A (pt)
BR (1) BRPI0919882A8 (pt)
CA (1) CA2742324A1 (pt)
IL (2) IL212591A (pt)
WO (1) WO2010062706A2 (pt)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136311A (en) 1996-05-06 2000-10-24 Cornell Research Foundation, Inc. Treatment and diagnosis of cancer
US8021847B2 (en) 2004-06-02 2011-09-20 Proxy Life Science Holdings, Inc. Microvesicle-based compositions and methods
EP1766053A4 (en) * 2004-06-02 2007-12-12 Sourcepharm Inc MICROVESICLES CONTAINING RNA AND METHODS
EP1996716B1 (en) 2006-03-20 2011-05-11 The Regents of the University of California Engineered anti-prostate stem cell antigen (psca) antibodies for cancer targeting
US8540752B2 (en) * 2007-07-03 2013-09-24 Spine Tek, Inc. Interspinous mesh
CA2733672C (en) 2007-08-16 2018-09-11 The Royal Institution For The Advancement Of Learning/Mcgill University Tumor cell-derived microvesicles
US20100255514A1 (en) 2007-08-16 2010-10-07 The Royal Institution For The Advancement Of Learning/Mcgill University Tumor cell-derived microvesicles
CA2698343C (en) * 2007-09-04 2018-06-12 The Regents Of The University Of California High affinity anti-prostate stem cell antigen (psca) antibodies for cancer targeting and detection
EP2198296B1 (en) * 2007-09-05 2015-11-11 Laurentian University Method of using tumour rna integrity to measure response to chemotherapy in cancer patients
US20100291113A1 (en) * 2007-10-03 2010-11-18 Cornell University Treatment of Proliferative Disorders Using Antibodies to PSMA
US20100069616A1 (en) * 2008-08-06 2010-03-18 The Regents Of The University Of California Engineered antibody-nanoparticle conjugates
EP2324126B1 (en) 2008-08-12 2014-04-23 Zinfandel Pharmaceuticals, Inc. METHOD OF IDENTIFYING Alzheimer's DISEASE RISK FACTORS
US8846315B2 (en) 2008-08-12 2014-09-30 Zinfandel Pharmaceuticals, Inc. Disease risk factors and methods of use
CA2742324A1 (en) * 2008-10-30 2010-06-03 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Methods for assessing rna patterns
US20140113310A9 (en) * 2008-12-05 2014-04-24 Myriad Genetics, Incorporated Cancer detection markers
ES2712732T3 (es) * 2009-02-17 2019-05-14 Cornell Res Foundation Inc Métodos y kits para el diagnóstico de cáncer y la predicción de valor terapéutico
US20120231970A1 (en) * 2009-09-30 2012-09-13 Japan Health Sciences Foundation Colon cancer marker and method for testing for colon cancer
EP2316972A1 (en) * 2009-10-29 2011-05-04 Deutsches Krebsforschungszentrum Circulating miRNAs as non-invasive markers for diagnosis and staging in prostate cancer
CA2782284A1 (en) 2009-11-30 2011-06-03 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Methods and systems for isolating, storing, and analyzing vesicles
RU2673908C2 (ru) 2009-12-02 2018-12-03 Имэджинэб, Инк. Мини-антитела j591 и цис-диатела для направленной доставки простата-специфичного мембранного антигена (psma) человека и способы их применения
US9624491B2 (en) * 2010-02-26 2017-04-18 Memorial Sloan Kettering Cancer Center Methods and compositions for the detection and treatment of cancer involving miRNAs and miRNA inhibitors and targets
CA2791905A1 (en) 2010-03-01 2011-09-09 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Biomarkers for theranostics
JP2013526852A (ja) 2010-04-06 2013-06-27 カリス ライフ サイエンシズ ルクセンブルク ホールディングス 疾患に対する循環バイオマーカー
WO2011156734A2 (en) * 2010-06-11 2011-12-15 Hitachi Chemical Co., Ltd. Method of characterizing vascular diseases
WO2011156763A1 (en) 2010-06-11 2011-12-15 Hitachi Chemical Co., Ltd. Methods for characterizing kidney function
DK3147373T3 (da) 2010-07-27 2019-08-12 Genomic Health Inc Fremgangsmåde til anvendelse af genekspression til at bestemme prognosen for prostatacancer
EP2942403B1 (en) * 2010-12-01 2017-04-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for predicting the outcome of a cancer by analysing mirna expression
MX355479B (es) 2011-01-10 2018-04-19 Zinfandel Pharmaceuticals Inc Metodos y productos de farmaco para tratar enfermedad de alzheimer.
EP2691548B1 (en) 2011-03-31 2017-11-22 University of Houston Microrna 130a,b as a tumor suppressor and sensitizing agent for chemotherapy
WO2012135814A2 (en) * 2011-03-31 2012-10-04 University Of Houston Microrna29a,b,c as a tumor suppressor and sensitizing agent for chemotherapy
JP6163479B2 (ja) * 2011-04-14 2017-07-12 エクサレンズ バイオサイエンス リミテッド 肝細胞癌の診断、予後診断、監視および治療方法
WO2012161124A1 (ja) * 2011-05-20 2012-11-29 国立大学法人愛媛大学 マイクロｒｎａ又はその発現系を含む組成物
JP5823031B2 (ja) 2011-06-10 2015-11-25 日立化成株式会社 小胞捕捉デバイスおよびそれを用いるための方法
BR112013032232A2 (pt) * 2011-06-16 2016-09-20 Caris Life Sciences Switzerland Holdings S A R L método de caracterização de câncer através do uso de biomarcador de ácido nucleico
US8759313B2 (en) 2011-08-03 2014-06-24 The Charlotte-Mecklenburg Hospital Authority Treatment of fibrosis using microRNA 19b
BR112014002975A2 (pt) * 2011-08-08 2017-03-01 Caris Life Sciences Luxembourg Holdings S A R L composições de biomarcador e métodos
CA2881501A1 (en) 2011-08-10 2013-02-14 Laurentian University Of Sudbury Diagnostic methods and kits for monitoring response to chemotherapy in ovarian cancer
EP3492606B1 (en) * 2011-08-22 2023-10-04 Exosome Diagnostics, Inc. Urine biomarkers
US20150024389A1 (en) * 2011-09-16 2015-01-22 Lsip, Llc Method for detecting bladder cancer cells, primer used in method for detecting bladder cancer cells, and bladder cancer marker
ES2691296T3 (es) * 2012-04-03 2018-11-26 Reneuron Limited Micropartículas de células madre
EP2653554A1 (en) * 2012-04-17 2013-10-23 Istituto Nazionale Di Genetica Molecolare-INGM Immune response biomarkers
AU2013252445B2 (en) 2012-04-24 2018-01-18 Rna Diagnostics Inc. Assays, methods and apparatus for assessing RNA disruption
US8846316B2 (en) 2012-04-30 2014-09-30 Industrial Technology Research Institute Biomarker for human liver cancer
WO2014030602A1 (ja) 2012-08-20 2014-02-27 独立行政法人国立がん研究センター 癌治療剤
KR101933620B1 (ko) * 2012-09-18 2018-12-28 삼성전자주식회사 소포를 검출하기 위한 조성물, 키트 및 이를 이용하여 소포를 분석하는 방법
BR112015009138A2 (pt) 2012-10-23 2020-10-20 Caris Life Sciences Switzerland Holdings, S.A.R.L. métodos para caracterizar um câncer
US10942184B2 (en) 2012-10-23 2021-03-09 Caris Science, Inc. Aptamers and uses thereof
WO2014071226A1 (en) 2012-11-02 2014-05-08 The Regents Of The University Of California Methods and systems for determining a likelihood of adverse prostate cancer pathology
CN102912030B (zh) * 2012-11-08 2014-07-30 端鹏 用于前列腺癌早期诊断的引物对、探针和试剂盒
EP2925892B1 (en) 2012-12-03 2019-02-06 RNA Diagnostics Inc. Methods for monitoring response to radiation therapies in cancer
AU2013361323B2 (en) 2012-12-19 2018-09-06 Caris Science, Inc. Compositions and methods for aptamer screening
KR101504817B1 (ko) * 2013-04-05 2015-03-24 연세대학교 산학협력단 국소 진행형 위암에 대한 예후 예측 시스템
US9662649B2 (en) 2013-05-06 2017-05-30 Hitachi Chemical Company America, Ltd. Devices and methods for capturing target molecules
CN104164474A (zh) * 2013-05-17 2014-11-26 刘代新 一种检测尿液中pca3基因和psa基因表达量的荧光定量pcr法及其诊断试剂盒
GB201317887D0 (en) 2013-10-09 2013-11-20 Reneuron Ltd Product
JP2016533752A (ja) * 2013-08-28 2016-11-04 カリス ライフ サイエンシズ スウィッツァーランド ホー オリゴヌクレオチドプローブおよびその使用
US9550989B2 (en) * 2013-10-03 2017-01-24 Washington University Rational design of microRNA-siRNA chimeras for multi-functional target suppression
US10731222B2 (en) 2013-10-04 2020-08-04 Rna Diagnostics Inc. RNA disruption assay for predicting survival
GB201322034D0 (en) 2013-12-12 2014-01-29 Almac Diagnostics Ltd Prostate cancer classification
CN103882118A (zh) * 2014-02-13 2014-06-25 绍兴市人民医院 用于检测前列腺癌的miRNAs
CN117965741A (zh) 2014-05-30 2024-05-03 东丽株式会社 胰腺癌的检测试剂盒或装置以及检测方法
CN107076747B (zh) * 2014-06-04 2021-02-02 阿托萨治疗学公司 分子乳房摄影术
CN111996254A (zh) 2014-06-12 2020-11-27 东丽株式会社 前列腺癌的检测试剂盒或装置以及检测方法
CN113151468A (zh) 2014-06-13 2021-07-23 东丽株式会社 乳癌的检测试剂盒或装置以及检测方法
KR102585737B1 (ko) 2014-06-16 2023-10-10 국립연구개발법인 고쿠리츠간켄큐센터 위암의 검출 키트 또는 디바이스 및 검출 방법
US10266895B2 (en) 2014-11-05 2019-04-23 Hitachi Chemical Company Ltd. Exosomes and microvesicles in intestinal luminal fluids and stool and use of same for the assessment of inflammatory bowel disease
JP6631852B2 (ja) 2014-11-12 2020-01-15 日立化成株式会社 臓器障害を診断するための方法および装置
US20160160181A1 (en) * 2014-12-03 2016-06-09 Capricor Thera[eitocs, Inc. Processes for producing exosomes in reduced oxygen culture conditions
WO2016125243A1 (ja) * 2015-02-03 2016-08-11 株式会社日立製作所 エクソソーム測定方法及びエクソソーム抽出方法
AU2016287499B2 (en) 2015-06-29 2022-08-04 Caris Science, Inc. Therapeutic oligonucleotides
US10941176B2 (en) 2015-07-28 2021-03-09 Caris Science, Inc. Therapeutic oligonucleotides
CA2994951A1 (en) 2015-08-07 2017-02-16 Imaginab, Inc. Antigen binding constructs to target molecules
US11028443B2 (en) 2015-08-31 2021-06-08 Showa Denko Materials Co., Ltd. Molecular methods for assessing urothelial disease
WO2017155894A1 (en) 2016-03-07 2017-09-14 Cfgenome, Llc Noninvasive molecular controls
WO2017161357A1 (en) 2016-03-18 2017-09-21 Caris Science, Inc. Oligonucleotide probes and uses thereof
CA3025486A1 (en) 2016-05-25 2017-11-30 Caris Science, Inc. Oligonucleotide probes and uses thereof
WO2018147960A1 (en) 2017-02-08 2018-08-16 Imaginab, Inc. Extension sequences for diabodies
CN108841962B (zh) * 2018-08-01 2021-11-19 博奥生物集团有限公司 一种非小细胞肺癌检测试剂盒及其应用
US11535899B2 (en) 2018-08-10 2022-12-27 Toray Industries, Inc. Kit, device and method for detecting prostate cancer
CN111041081A (zh) * 2018-10-11 2020-04-21 伽蓝（集团）股份有限公司 一种以皮肤外源性老化靶标筛选活性物的方法及改善皮肤外源性老化的活性物
CN109136379A (zh) * 2018-10-15 2019-01-04 济南艾迪康医学检验中心有限公司 检测样本中NonO-TFE3融合基因的寡核苷酸、方法和试剂盒
CN109234362A (zh) * 2018-10-15 2019-01-18 北京艾迪康医学检验实验室有限公司 检测样本中cltc-tfe3融合基因的寡核苷酸、方法和试剂盒
KR20210111254A (ko) 2018-11-30 2021-09-10 캐리스 엠피아이, 아이엔씨. 차세대 분자 프로파일링
TWI758670B (zh) * 2018-12-24 2022-03-21 奎克生技光電股份有限公司 健康風險評估方法
CA3127113A1 (en) 2019-01-30 2020-08-06 Dongxu Sun Anti-gal3 antibodies and uses thereof
CN110305964B (zh) * 2019-07-26 2023-03-21 安徽医科大学第一附属医院 一种前列腺癌患者预后复发风险预测标志工具及其风险评估模型的建立
WO2021112918A1 (en) 2019-12-02 2021-06-10 Caris Mpi, Inc. Pan-cancer platinum response predictor
CN117255861A (zh) * 2022-01-28 2023-12-19 香港城市大学 测量多重rna表达的方法和系统
WO2023239920A1 (en) * 2022-06-10 2023-12-14 City Of Hope Biomarkers in pancreatic cancer

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3812023A (en) * 1972-12-11 1974-05-21 Reynolds Metals Co Anodic production of pigmented siliceous coatings for aluminous metals
US5700637A (en) 1988-05-03 1997-12-23 Isis Innovation Limited Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays
GB8822228D0 (en) 1988-09-21 1988-10-26 Southern E M Support-bound oligonucleotides
US6040138A (en) 1995-09-15 2000-03-21 Affymetrix, Inc. Expression monitoring by hybridization to high density oligonucleotide arrays
US5527681A (en) 1989-06-07 1996-06-18 Affymax Technologies N.V. Immobilized molecular synthesis of systematically substituted compounds
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5424186A (en) 1989-06-07 1995-06-13 Affymax Technologies N.V. Very large scale immobilized polymer synthesis
US5242974A (en) 1991-11-22 1993-09-07 Affymax Technologies N.V. Polymer reversal on solid surfaces
DE3924454A1 (de) 1989-07-24 1991-02-07 Cornelis P Prof Dr Hollenberg Die anwendung von dna und dna-technologie fuer die konstruktion von netzwerken zur verwendung in der chip-konstruktion und chip-produktion (dna chips)
EP1231282A3 (en) 1990-12-06 2005-05-18 Affymetrix, Inc. Methods and compositions for identification of polymers
IL103674A0 (en) 1991-11-19 1993-04-04 Houston Advanced Res Center Method and apparatus for molecule detection
US5412087A (en) 1992-04-24 1995-05-02 Affymax Technologies N.V. Spatially-addressable immobilization of oligonucleotides and other biological polymers on surfaces
US5384261A (en) 1991-11-22 1995-01-24 Affymax Technologies N.V. Very large scale immobilized polymer synthesis using mechanically directed flow paths
US5554501A (en) 1992-10-29 1996-09-10 Beckman Instruments, Inc. Biopolymer synthesis using surface activated biaxially oriented polypropylene
US5472672A (en) 1993-10-22 1995-12-05 The Board Of Trustees Of The Leland Stanford Junior University Apparatus and method for polymer synthesis using arrays
US5429807A (en) 1993-10-28 1995-07-04 Beckman Instruments, Inc. Method and apparatus for creating biopolymer arrays on a solid support surface
US5571639A (en) 1994-05-24 1996-11-05 Affymax Technologies N.V. Computer-aided engineering system for design of sequence arrays and lithographic masks
US5807522A (en) 1994-06-17 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for fabricating microarrays of biological samples
US5556752A (en) 1994-10-24 1996-09-17 Affymetrix, Inc. Surface-bound, unimolecular, double-stranded DNA
US5599695A (en) 1995-02-27 1997-02-04 Affymetrix, Inc. Printing molecular library arrays using deprotection agents solely in the vapor phase
US5624711A (en) 1995-04-27 1997-04-29 Affymax Technologies, N.V. Derivatization of solid supports and methods for oligomer synthesis
US5545531A (en) 1995-06-07 1996-08-13 Affymax Technologies N.V. Methods for making a device for concurrently processing multiple biological chip assays
US5658734A (en) 1995-10-17 1997-08-19 International Business Machines Corporation Process for synthesizing chemical compounds
PT938320E (pt) * 1996-03-26 2010-09-22 Michael S Kopreski Método que permite a utilização de arn extracelular extraído de plasma ou de soro para detectar, monitorizar ou avaliar o cancro
FR2766205B1 (fr) * 1997-07-16 2002-08-30 Inst Nat Sante Rech Med Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede
FR2788780B1 (fr) 1999-01-27 2001-03-30 Ap Cells Inc Procede de preparation de vesicules membranaires
GB9927320D0 (en) 1999-11-18 2000-01-12 Chiron Spa Exosome separation
US20040241176A1 (en) 2000-04-27 2004-12-02 Ap Cells. Inc. Method of producing membrane vesicles
US6812023B1 (en) * 2000-04-27 2004-11-02 Anosys, Inc. Methods of producing membrane vesicles
JP4662708B2 (ja) * 2001-08-17 2011-03-30 エクソセラ・エルエルシー エクソゾームにタンパク質を標的化する方法および組成物
US20070203333A1 (en) * 2001-11-30 2007-08-30 Mcswiggen James RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
AUPS187002A0 (en) * 2002-04-22 2002-05-30 Queensland University Of Technology Condition-specific molecules and uses therefor
AU2003291433B2 (en) * 2002-11-13 2008-05-22 Thomas Jefferson University Compositions and methods for cancer diagnosis and therapy
US7914792B2 (en) 2003-02-14 2011-03-29 Exothera L.L.C. Methods and compounds for raising antibodies and for screening antibody repertoires
GB0318096D0 (en) 2003-08-01 2003-09-03 Queen Mary & Westfield College Vaccine
CA2453198A1 (en) 2004-01-07 2005-07-07 Wei-Ping Min Quantification and generation of immune suppressive exosomes
PL1720611T3 (pl) * 2004-02-16 2010-09-30 Proteosys Ag Marker diagnostyczny dla raka
EP1766053A4 (en) 2004-06-02 2007-12-12 Sourcepharm Inc MICROVESICLES CONTAINING RNA AND METHODS
CA2491067A1 (en) * 2004-12-24 2006-06-24 Stichting Katholieke Universiteit Mrna rations in urinary sediments and/or urine as a prognostic marker for prostate cancer
US20060211000A1 (en) * 2005-03-21 2006-09-21 Sorge Joseph A Methods, compositions, and kits for detection of microRNA
CA2617581A1 (en) * 2005-08-01 2007-02-08 The Ohio State University Research Foundation Microrna-based methods for the diagnosis of breast cancer
US20070092882A1 (en) 2005-10-21 2007-04-26 Hui Wang Analysis of microRNA
US7197923B1 (en) * 2005-11-07 2007-04-03 Halliburton Energy Services, Inc. Single phase fluid sampler systems and associated methods
ES2461189T3 (es) 2006-01-05 2014-05-19 The Ohio State University Research Foundation Métodos basados en microARN y composiciones para el diagnóstico y el tratamiento de cánceres sólidos de mama o pulmón
CN102943108B (zh) * 2006-01-05 2014-05-21 俄亥俄州立大学研究基金会 用于肺癌的诊断、预后和治疗的基于微小rna的方法和组合物
EP1968622B1 (en) * 2006-01-05 2014-08-27 The Ohio State University Research Foundation Microrna expression abnormalities in pancreatic endocrine and acinar tumors
US7593913B2 (en) 2006-01-11 2009-09-22 Siemens Medical Solutions Usa, Inc. Systems and method for integrative medical decision support
US9394569B2 (en) * 2006-01-31 2016-07-19 The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center Methods and kits for early detection of cancer or predisposition thereto
US9198981B2 (en) 2006-02-01 2015-12-01 The University Of Kentucky Modulation of angiogenesis
EP2522750A1 (en) 2006-03-02 2012-11-14 The Ohio State University MicroRNA expression profile associated with pancreatic cancer
ES2736726T3 (es) 2006-03-09 2020-01-07 Aethlon Medical Inc Eliminación extracorpórea de partículas microvesiculares
US9085778B2 (en) 2006-05-03 2015-07-21 VL27, Inc. Exosome transfer of nucleic acids to cells
EP2589668A1 (en) * 2006-06-14 2013-05-08 Verinata Health, Inc Rare cell analysis using sample splitting and DNA tags
US7462489B2 (en) 2006-11-09 2008-12-09 Ley Klaus F Methods for identifying and analyzing biomarkers from plasma-derived microparticles
WO2008091948A2 (en) * 2007-01-23 2008-07-31 University Of Virginia Patent Foundation Galectin-3-binding, protein as a biomarker of cardiovascular disease
US8314220B2 (en) * 2007-01-26 2012-11-20 Agilent Technologies, Inc. Methods compositions, and kits for detection of microRNA
EP2117305A4 (en) * 2007-01-26 2011-03-30 Univ Louisville Res Found MODIFICATION OF EXOXIC COMPONENTS USED AS VACCINE
CN101657719A (zh) * 2007-01-26 2010-02-24 路易斯维尔大学研究基金会公司 检测用于诊断和表征障碍的自身抗体的方法
US8034560B2 (en) * 2007-01-31 2011-10-11 The Ohio State University Research Foundation MicroRNA-based methods and compositions for the diagnosis, prognosis and treatment of acute myeloid leukemia (AML)
WO2008112283A2 (en) 2007-03-12 2008-09-18 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Microrna profiling of androgen responsiveness for predicting the appropriate prostate cancer treatment
US20100178653A1 (en) * 2007-03-27 2010-07-15 Rosetta Genomics Ltd. Gene expression signature for classification of cancers
WO2008138578A2 (en) 2007-05-11 2008-11-20 Medical Prognosis Institute Methods, kits, and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
EP2806273B1 (en) 2007-07-25 2017-09-06 University of Louisville Research Foundation, Inc. Exosome-associated microRNA as a diagnostic marker
WO2009019215A1 (en) 2007-08-03 2009-02-12 Dkfz Deutsches Krebsforschungszentrum Method for prenatal diagnosis using exosomes and cd24 as a marker
CA2733672C (en) 2007-08-16 2018-09-11 The Royal Institution For The Advancement Of Learning/Mcgill University Tumor cell-derived microvesicles
ES2575868T3 (es) 2007-09-14 2016-07-01 The Ohio State University Research Foundation Expresión de miARN en microvesículas de sangre periférica humana y sus usos
US8895525B2 (en) 2007-10-29 2014-11-25 University Of Southern California Preventing hyaluronan-mediated tumorigenetic mechanisms using intronic RNAs
CA2707157A1 (en) 2007-11-30 2009-06-04 The Ohio State University Research Foundation Microrna expression profiling and targeting in peripheral blood in lung cancer
US8617806B2 (en) 2008-01-25 2013-12-31 Hansabiomed Ou Method to measure and characterize microvesicles in the human body fluids
AU2009209415A1 (en) 2008-02-01 2009-08-06 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions relating to carcinoma stem cells
US20110053157A1 (en) 2008-02-01 2011-03-03 The General Hospital Corporation Use of microvesicles in diagnosis, prognosis and treatment of medical diseases and conditions
EP3112477A1 (en) 2008-02-28 2017-01-04 The Ohio State University Research Foundation Microrna-based methods and compositions for the diagnosis, prognosis and treatment of prostate related disorders
US20110177054A1 (en) 2008-06-06 2011-07-21 Derrick Gibbings Use of endo-lysosomal system and secreted vesicles (exosome-like) in treatments and diagnostics based on small rna and experimental study of small rna
CN102105598A (zh) 2008-06-20 2011-06-22 代理生命科学控股公司 基于微泡的组合物和方法
EP2334339A4 (en) 2008-09-18 2012-09-26 Univ Ohio State Res Found DIAGNOSTIC, PROGNOSTIC AND THERAPEUTIC USE OF MIRS IN ADAPTIVE SIGNALING PATHS AND / OR DISEASE SIGNALS
US10545149B2 (en) * 2008-10-06 2020-01-28 Morehouse School Of Medicine Detection of HIV-related proteins in urine
CA2742324A1 (en) * 2008-10-30 2010-06-03 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Methods for assessing rna patterns
EP2350320A4 (en) * 2008-11-12 2012-11-14 Caris Life Sciences Luxembourg Holdings METHODS AND SYSTEMS FOR USING EXOSOMES TO DETERMINE PHENOTYPES
GB0822836D0 (en) 2008-12-15 2009-01-21 Oxford Biomedica Ltd Method

Also Published As

Publication number Publication date
EP2358912A2 (en) 2011-08-24
BRPI0919882A2 (pt) 2016-02-16
EP2358912B1 (en) 2016-10-12
IL233188A0 (en) 2014-07-31
US20100113290A1 (en) 2010-05-06
WO2010062706A2 (en) 2010-06-03
US20110159506A1 (en) 2011-06-30
IL233188A (en) 2016-05-31
US20130045882A1 (en) 2013-02-21
IL212591A (en) 2014-07-31
EP2358912A4 (en) 2012-10-31
CN102308004A (zh) 2012-01-04
JP2012507300A (ja) 2012-03-29
CA2742324A1 (en) 2010-06-03
US7888035B2 (en) 2011-02-15
IL212591A0 (en) 2011-07-31
US8192954B2 (en) 2012-06-05
WO2010062706A3 (en) 2010-09-02

Similar Documents

Publication Publication Date Title
BRPI0919882A8 (pt) Métodos para avaliar padrões de rna
MX2017010836A (es) Panel biomarcador para la deteccion de cancer.
WO2013106844A3 (en) Methods and compositions for the treatment and diaginosis of pancreatic cancer
EP2576837A4 (en) CIRCULATING NUCLEIC ACID BIOMARKERS ASSOCIATED WITH PROSTATE CANCER
WO2009111643A3 (en) Microrna markers for recurrence of colorectal cancer
WO2010096154A3 (en) Compositions and methods for diagnosis and prognosis of colorectal cancer
MX2014000116A (es) Metodos y acidos nucleicos para determinar el pronostico de un sujeto con cancer.
EA200971079A1 (ru) ГЕНЕТИЧЕСКИЕ ВАРИАНТЫ В Chr5p12 И 10q26 В КАЧЕСТВЕ МАРКЕРОВ ДЛЯ ПРИМЕНЕНИЯ ПРИ ОЦЕНКЕ РИСКА, ДИАГНОСТИРОВАНИИ, ПРОГНОЗИРОВАНИИ И ЛЕЧЕНИИ РАКА ГРУДИ
WO2013033627A3 (en) Diagnosis and treatment of arthritis using epigenetics
WO2014071358A3 (en) Novel ntrk1 fusion molecules and uses thereof
WO2010045318A3 (en) Gene and gene expressed protein targets depicting biomarker patterns and signature sets by tumor type
EA200970695A1 (ru) Способы и нуклеиновые кислоты для анализов нарушений клеточной пролиферации
BRPI0801193A2 (pt) detecÇço de cÂncer de pràstata
WO2013148147A8 (en) Dna methylation analysis for the diagnosis, prognosis and treatment of adrenal neoplasms
BRPI0718850A2 (pt) Métodos de tratar, diagnosticar ou detectar câncer
WO2012096545A3 (ko) 췌장암 암줄기세포 특성을 이용한 췌장암 신규 바이오마커 및 그의 용도
WO2008117314A3 (en) Genetic variants on chr2 and chr16 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
WO2014057357A3 (en) Method for the diagnosis, prognosis and treatment of prostate cancer metastasis using c-maf
WO2010120942A3 (en) Histone modification patterns for clinical diagnosis and prognosis of cancer
MX2013000502A (es) Metodos y kits para el diagnostico de cancer de prostata.
WO2013172779A3 (en) Method for indicating the presence or non-presence of prostate cancer
WO2011106104A3 (en) Methods and compositions for the detection and treatment of cancer involving mirnas and mirna inhibitors and targets
WO2008023840A3 (en) Prognostic markers and therapeutic targets for lung cancer
EP2558597A4 (en) EARLY DETECTION AND STADIFICATION OF COLORECTAL CANCER USING A MICRO-RNA PANEL
ZA200808669B (en) Methods of treating, diagnosing or detecting cancer

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B25D Requested change of name of applicant approved

Owner name: CARIS LIFE SCIENCES SWITZERLAND HOLDINGS GMBH (CH)

B25G Requested change of headquarter approved

Owner name: CARIS LIFE SCIENCES SWITZERLAND HOLDINGS GMBH (CH)

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]